Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
MicroRNA and Cancer Immunology
share announcement

MicroRNA and Cancer Immunology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 15 September 2025 | Viewed by 1359

Special Issue Editor

Dr. Behzad Mansoori

E-Mail Website
Guest Editor
Cellular and Molecular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA
Interests: oncology; immunology; targeted therapy; genomics; bioinformatic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to this Special Issue on “MicroRNA and Cancer Immunology” in Cancers. This issue seeks to illuminate the critical role of microRNAs (miRNAs) in the complex interplay within the tumor microenvironment and their impact on cancer progression. Recent research underscores the significance of miRNAs as modulators of immune cell function, tumor angiogenesis, and epithelial–mesenchymal transition (EMT). Their potential as biomarkers and therapeutic targets in cancer diagnosis, prognosis, and treatment highlights the importance of this burgeoning field.

This Special Issue aims to collate and disseminate cutting-edge research and reviews exploring the multifaceted roles of miRNAs in cancer immunology. Our goal is to provide a comprehensive overview of current advances and encourage discussions that may shape future research directions in this vital area.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • miRNA roles in tumor microenvironment modulation and tumor evasion.
  • New miRNA targets that affect both cancer progression and EMT.
  • The impact of miRNA on tumor angiogenesis and metastasis.
  • miRNA as biomarkers for cancer diagnosis and prognosis.
  • Therapeutic potential of miRNA in cancer treatment.
  • Novel methodologies in miRNA research related to cancer immunology.
  • miRNA which involves immunometabolism in cancer.

We look forward to receiving your contributions and fostering a rich dialogue in this dynamic and vital field of cancer research.

Dr. Behzad Mansoori
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA
  • miRNA
  • tumor microenvironment
  • biomarkers
  • cancer immunology
  • cancer treatment
  • therapeutic target
  • tumor angiogenesis
  • tumor metastasis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

38 pages, 2269 KiB  
Review
MicroRNAs in Cancer Immunology: Master Regulators of the Tumor Microenvironment and Immune Evasion, with Therapeutic Potential
by Erfan Zare, Seyyed Mohammad Yaghoubi, Maedeh Khoshnazar, Sina Jafari Dargahlou, Janvhi Suresh Machhar, Zihan Zheng, Pascal H. G. Duijf and Behzad Mansoori
Cancers 2025, 17(13), 2172; https://doi.org/10.3390/cancers17132172 - 27 Jun 2025
Viewed by 452
Abstract
MicroRNAs (miRNAs) are pivotal modulators of tumor progression and immune function. Given the central role of the immune system in recognizing and eliminating malignant cells, understanding how miRNAs influence immune responses has become essential for advancing cancer therapy. This review explores the emerging [...] Read more.
MicroRNAs (miRNAs) are pivotal modulators of tumor progression and immune function. Given the central role of the immune system in recognizing and eliminating malignant cells, understanding how miRNAs influence immune responses has become essential for advancing cancer therapy. This review explores the emerging roles of miRNAs in orchestrating cancer immunology, emphasizing their regulation of tumor immune surveillance, immune equilibrium, immune evasion, and immunometabolism. We further illustrate how specific miRNAs modulate the tumor microenvironment by shaping immune cell phenotypes, cytokine networks, and antigen presentation. Some miRNAs enhance cytotoxic T lymphocyte activity, while others promote immune escape by expanding regulatory T cells and myeloid-derived suppressor cells. miRNAs also regulate immune checkpoints (e.g., PD-L1 and CTLA-4), metabolic reprogramming, and stress responses that collectively influence tumor immunogenicity. Additionally, miRNAs are gaining traction as biomarkers for immune activity and predictors of immunotherapy response. Therapeutically, miRNA mimics and inhibitors can enhance anti-tumor immunity, particularly when combined with advanced delivery platforms or immune checkpoint inhibitors. However, challenges such as delivery specificity, off-target effects, and the context-dependent nature of miRNA activity remain significant barriers to clinical translation. Despite shortcomings, miRNAs represent a class of immune regulators with substantial therapeutic potential. Accelerated progress in miRNA-guided therapies is anticipated through deepening insights into miRNA regulatory networks, coupled with integrative multi-omics and AI-driven analytical frameworks. Altogether, miRNAs are a promising frontier in next-generation cancer immunotherapy and precision oncology. Full article
(This article belongs to the Special Issue MicroRNA and Cancer Immunology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop